Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives.

OBJECTIVE Inherited resistance to activate protein C, which is caused by a single factor V gene mutation, is a frequent risk factor for thrombosis. The purpose of this study was to determine the prevalence of activated protein C resistance in women with thromboembolic complications that had occurred in connection with pregnancy or use of oral contraceptives. STUDY DESIGN Activated protein C resistance was analyzed in women with previous thromboembolic complications in connection with pregnancy (n = 34) or oral contraceptives (n = 28), in healthy fertile women (n = 57), and in women during normal pregnancy (n = 18). Results of the activated protein C resistance test were expressed as activated protein C ratios, values < 2 indicating activated protein C resistance. RESULTS Activated protein C resistance was found in almost 60% of women with thromboembolic complications during pregnancy and in around 30% of women with thromboembolic complications during treatment with oral contraceptives. In nonpregnant controls approximately 10% had activated protein C resistance. In normal pregnancy activated protein C ratios were similar to those of normal controls. CONCLUSIONS Activated protein C resistance, which is caused by a genetic defect in the factor V gene, was found to be highly prevalent in women with a history of thromboembolic complications during pregnancy. The gene defect is common in the general population, and the results evoke the question whether it would be reasonable to perform general screening for activated protein C resistance early during pregnancy or before prescription of oral contraceptives.

[1]  B. Dahlbäck,et al.  Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. , 1994, The Journal of clinical investigation.

[2]  B. Dahlbäck.  Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. , 1994, The Journal of clinical investigation.

[3]  B. Dahlbäck,et al.  Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis , 1994, The Lancet.

[4]  J. Voorberg,et al.  Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V , 1994, The Lancet.

[5]  J. Griffin,et al.  Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia , 1994 .

[6]  B. Evatt,et al.  Activated protein C resistance caused by Arg506Gln mutation in factor Va , 1994, The Lancet.

[7]  A. Lavin,et al.  Varicella-zoster vaccination for health care workers , 1994, The Lancet.

[8]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[9]  B. Dahlbäck,et al.  Resistance to activated protein C as a basis for venous thrombosis. , 1994, The New England journal of medicine.

[10]  B. Dahlbäck,et al.  Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  W. Halbmayer,et al.  The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[12]  E. Sacchi,et al.  Resistance to Activated Protein C in Nine Thrombophilic Families: Interference in a Protein S Functional Assay , 1993, Thrombosis and Haemostasis.

[13]  F. Rosendaal,et al.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study , 1993, The Lancet.

[14]  J. Griffin,et al.  Anticoagulant protein C pathway defective in majority of thrombophilic patients. , 1993, Blood.

[15]  B. Dahlbäck,et al.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[16]  B. Dahlbäck,et al.  Thromboembolic Disease – Critical Evaluation of Laboratory Investigation , 1992, Thrombosis and Haemostasis.

[17]  H. Büller,et al.  Deep Vein Thrombosis in Obstetric Patients: Diagnosis and Risk Factors , 1992, Thrombosis and Haemostasis.

[18]  Sipes Sl,et al.  Venous thromboembolic disease in pregnancy. , 1990 .

[19]  B. Ransil,et al.  Maternal Mortality in Massachusetts—Trends and Prevention , 1987, The New England journal of medicine.

[20]  U. Högberg.  Maternal Deaths in Sweden, 1971–1980 , 1986, Acta obstetricia et gynecologica Scandinavica.

[21]  A. Bloom.  Haemostasis and thrombosis , 1981 .

[22]  B. Westerholm,et al.  Oral contraceptives and thromboembolic disease. Swedish experience. , 2009 .

[23]  D. W. Calhoun,et al.  Oral contraceptives and thromboembolic disease. , 1968, JAMA.